Rapid health technology assessment of selexipag in the treatment of pulmonary arterial hypertension
- VernacularTitle:司来帕格治疗肺动脉高压的快速卫生技术评估
- Author:
Wenxing DONG
1
;
Zhe ZHANG
1
;
Jiang WANG
2
;
Rufu XU
1
;
Mingming CHU
1
;
Rong ZHANG
1
Author Information
1. Dept. of Pharmacy，the Second Affiliated Hospital of Army Medical University，Chongqing 400037，China
2. Dept. of Cardiology，the Second Affiliated Hospital of Army Medical University，Chongqing 400037，China
- Publication Type:Journal Article
- Keywords:
selexipag;
pulmonary a rterial hypertension;
rapid health techn ology assessment
- From:
China Pharmacy
2022;33(20):2524-2528
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the efficacy ，safety，and economy of selexipag in the treatment of pulmonary arterial hypertension（PAH）. METHODS After literature screening ，data extraction and quality evaluation ，the results of included studies were analyzed descriptively by retrieving PubMed ，Embase，Web of Science ，Cochrane Library ，Epistemonikos，SinoMed， CNKI，VIP，Wanfang data ，CBM，official websites of domestic and foreign health technology assessment institutions and relevant database. RESULTS&CONCLUSIONS A total of 7 literature were included ，involving 6 meta-analysis and 1 pharmacoeconomic study. In terms of efficacy ，selexipag could improve patients ’exercise tolerance and hemodynamic indexes ，and reduced the incidence of clinical worsening events and hospitalization . However，intravenous/subcutaneous administration of prostacyclin analog had better effects in improving WHO functional class and reducing all -cause mortality （P＜0.05）. There were no statistically significant differences in the impact on outcome indexes between selexipag and other targeted agents （P＞0.05）. In terms of safety ， the incidence of adverse drug events and drug withdrawal due to adverse reactions was increased by selexipag （P＜0.05），but there were no significant differences between the effects of selexipag and other targeted drugs on adverse events ，serious adverse events and drug withdrawal due to adverse reactions （P＞0.05）. In terms of economy ，based on the background of Canada ’s health system，it was not economical for selexipag to treat PAH ，and there was a lack of economic research based on China ’s national conditions. Further comparative studies on the efficacy and economics of selexipag and prostacyclins in the real world are needed .
